SCHEMBL4034657

SCHEMBL4034657

CN(C)c1cccc(C2(C(C(=O)NC3CCCCC3)C3CCCCC3)Nc3ccccc3N2)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
KDM4E B2RXH2 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
GFER P55789 1/20 0.50
HSD17B10 Q99714 1/20 0.50
HTT P42858 1/20 0.46
PKM P14618 1/20 0.43
POLB P06746 1/20 0.42
NR1H4 Q96RI1 1/20 0.40
EPHX1 P07099 1/20 0.39
ACKR3 P25106 1/20 0.38
IDH1 O75874 2/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
BACE1 P56817 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4038970 0.92 NPC1 (0.48) SMN1; SMN2KDM4ENPC1RAB9AGFER
SCHEMBL4045003 0.91 NPC1 (0.46) SMN1; SMN2KDM4ENPC1RAB9AGFER
SCHEMBL4037171 0.86 NPC1 (0.47) SMN1; SMN2NPC1RAB9ATSHRKMT2A
SCHEMBL4038973 0.85 NPC1 (0.46) SMN1; SMN2NPC1RAB9AHTTPOLB
SCHEMBL4042940 0.85 TSHR (0.45) SMN1; SMN2KDM4ENPC1RAB9AHSD17B10
SCHEMBL4040716 0.83 PKM (0.44) SMN1; SMN2NPC1RAB9APKMEPHX1
SCHEMBL4039067 0.82 NPC1 (0.44) SMN1; SMN2KDM4ENPC1RAB9AHSD17B10
SCHEMBL4036803 0.82 L3MBTL1 (0.45) SMN1; SMN2KDM4ERAB9AHTTKMT2A
SCHEMBL4044228 0.82 TSHR (0.41) SMN1; SMN2KDM4ENPC1RAB9AHSD17B10
SCHEMBL4039200 0.82 PKM (0.50) SMN1; SMN2NPC1RAB9AHTTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed